Connect with us

Featured Stocks

Planet 13 Holdings Inc. (CSE: PLTH) (OTC: PLNHF) Increasing its Visibility with the Phase II Expansion Plan Underway

Published

on

Planet 13 Holdings

Planet 13 Holdings Inc. (CSE: PLTH) (OTC: PLNHF) stock looks to be a good long term investment for cannabis investors. As a vertically-integrated company in the emerging cannabis market, it’s strategically positioned for growth. Interestingly, it was quite recently that the stock really jumped on to the radar and the one spark that fanned the flame is its statistics on the Las Vegas Cannabis Entertainment Complex.

Planet 13 Holdings Inc. Price Analysis

Planet 13 Holdings Inc. is headquartered in Las Vegas, Nevada and as of the press time, the stock price is 2.10 USD.


PLNHF price today.

Steady but Strong Planet 13

The company has been performing well with some strong growth in its first two quarters of 2018. The firm is mainly focused on providing an array of international award-winning marijuana products as well as providing an unparalleled dispensary experience.

To ensure that Planet 13 Holdings comes on top, it has taken significant steps, for instance, phase two planned expansions are already underway.

New Production Facility

In early November, Planet 13 launched its first phase of 112,000 sq. Ft. cannabis entertainment complex near Las Vegas and a 16,200 square foot dispensary. The retail dispensary is the largest and most advanced in the world.

Besides, there’s also TRENDI which specializes in expertly crafted cannabis products which create the trend, and not the other way around. The company utilizes cutting edge technology as well as a unique visual approach and hence is able to deliver some exceptional products.

The new facility is meant to enable Planet 13 to meet the rapidly growing demand for TRENDI concentrate as well as vape lines. Also, it’s for addressing the overwhelming demand for the company’s Medizin line. In general, the entire Phase II expansion is expected to cost about US$6 million.

Mike Tyson Deal

The company also signed an agreement with the cannabis venture of Mike Tyson (former heavyweight champion), where it became an exclusive launch alliance of Tyson Ranch products in Nevada.

It means that Tyson Ranch products are available in its superstore shelves.

By the Numbers

As it was expected, after opening the mega superstore, the company recorded an impressive number of customers per day last month with a total of 1,962 at an average ticket of $89.62.

According to Co-CEO of Planet 13, the results were meeting the 2000 customers per day at an average ticket of $75 that they guided to during the opening of the superstore. It should be clear that it’s only 35% of the square footage that has already been built.

Therefore, more visibility is expected to continue growing once the phase II expansion is complete.

Besides, Planet 13 had $5.49 million in revenue from the cannabis entertainment complex in Las Vegas. It means that the superstore revenue has now grown almost 63.4% from November and 13.1% compounded monthly rate.

Moreover, the latest record is that the superstore saw over 6,000 visitors with almost 3,500 paying customers and an average ticket of US$91.11

Bottom Line

PLNHF is simply an exciting play coming into the cannabis space. With the new TRENDI brand as well as the superstore in Las Vegas strip as a base and recording new results each day, Planet 13 is only getting better.

Undoubtedly, Planet 13 is primed for growth as well as ready for the new markets as legalization for cannabis in the US continues. For a serious cannabis investor, PLNHF looks to be a must-own.

For the latest updates on PLNHF and the hottest MJ stocks, sign up below!

Disclosure: We have no position in PLNHF and have not been compensated for this article.

Image courtesy of Pexels

Continue Reading
Click to comment

Featured Stocks

Forget APHA and ACB, Buy GTBIF and TCNNF

Published

on

GTBIF TCNNF

There are a lot of misconceptions going on when it comes to US legalization. Many investors are buying Aphria (APHA) and Aurora Cannabis (ACB) hoping to bank on what’s happening in the US. However, they are Canadian Licensed Producers and have no business in the US. Investors are buying them because they trade on the major exchanges, but that is the wrong move. The correct move is to buy the US multi-state operators like Green Thumb Industries (GTBIF) and Trulieve Cannabis (TCNNF).

On Election Day voters in New Jersey, Arizona, Montana and South Dakota voted to legalize recreational marijuana. South Dakota and Mississippi voters also approved measures to legalize medical marijuana.

There’s also the prospect of a more pot-friendly White House with President-elect Joe Biden. Vice Presidential Candidate Kamala Harris said at the debate a Biden administration would decriminalize marijuana at a federal level and expunge criminal records of people with marijuana-related offenses.

GTBIF

Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves.

Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomon’s, incredibles, Rythm and The Feel Collection.

The company also owns and operates rapidly growing national retail cannabis stores called Rise™ and Essence. Headquartered in Chicago, Illinois, Green Thumb has 13 manufacturing facilities, licenses for 96…

Continue Reading

Featured Stocks

Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity

Published

on

OTCMKTS:DECN

Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.

OTCMKTS:DECN Price Analysis

The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.

OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.

DECN Daily Chart

Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.

About OTCMKTS:DECN

Decision Diagnostics bills itself…

Continue Reading

Featured Stocks

Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?

Published

on

CytoDyn

CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.

The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.

Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.

About CytoDyn

CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.

Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.

CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment

CytoDyn’s lead drug candidate leronlimab (PRO 140)…

Continue Reading

MJ Stocks